AXNX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AXNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Axonics is: High Risk: High uncertainty with risk-return tradeoff.
For the Medical Devices subindustry, Axonics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Axonics's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Axonics's Risk Assessment falls into.
Axonics (NAS:AXNX) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of Axonics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Karen Noblett | officer: Chief Medical Officer | 26 TECHNOLOGY DRIVE, IRVINE CA 92618 |
Kari Leigh Keese | officer: Chief Financial Officer | 15205 LAFAYETTE WAY, TUSTIN CA 92782 |
Danny L. Dearen | officer: See Remarks | 26 TECHNOLOGY DRIVE, IRVINE CA 92618 |
Ford Alfred J Jr | officer: Chief Commercial Officer | 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021 |
Rinda Sama | officer: Chief Operating Officer | 26 TECHNOLOGY DRIVE, IRVINE CA 92618 |
John Woock | officer: Chief Marketing Officer | 26 TECHNOLOGY DRIVE, IRVINE CA 92618 |
Raymond W Cohen | director, officer: Chief Executive Officer | |
Esteban Lopez | director | 6303 COWBOYS WAY, SUITE 600, FRISCO TX 75034 |
Jane E Kiernan | director | 525 W ROSCOE, CHICAGO IL 60657 |
Robert Mcnamara | director | C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750 |
David M Demski | director | C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
Robert E Mcnamara | director | C/O NORTHSTAR NEUROSCIENCE, INC., 2401 FOURTH AVENUE, SUITE 300, SEATTLE WA 98121 |
Bakker Juliet Tammenoms | director, 10 percent owner | LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Partners Andera | 10 percent owner | 374 RUE SAINT ST HONORE, PARIS I0 75001 |
Raphael Wisniewski | director, 10 percent owner | 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920 |
From GuruFocus
By GuruFocus Research • 09-22-2023
By Business Wire Business Wire • 03-29-2023
By Business Wire • 10-02-2023
By Business Wire • 01-08-2024
By Business Wire Business Wire • 01-11-2023
By PRNewswire • 01-08-2024
By Business Wire Business Wire • 12-21-2022
By Business Wire • 08-25-2023
By Business Wire Business Wire • 04-25-2023
By Business Wire Business Wire • 01-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.